Header Logo

Connection

Lynn Morris to Sequence Analysis, DNA

This is a "connection" page, showing publications Lynn Morris has written about Sequence Analysis, DNA.
Connection Strength

0,956
  1. High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell. 2019 12 12; 179(7):1636-1646.e15.
    View in: PubMed
    Score: 0,160
  2. Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Virol Methods. 2014 Oct; 207:182-7.
    View in: PubMed
    Score: 0,110
  3. Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology. 2013 Nov; 446(1-2):66-76.
    View in: PubMed
    Score: 0,103
  4. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Nov; 24(11):1449-54.
    View in: PubMed
    Score: 0,074
  5. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology. 2006 Dec 5-20; 356(1-2):95-105.
    View in: PubMed
    Score: 0,064
  6. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses. 2006 May; 22(5):458-65.
    View in: PubMed
    Score: 0,062
  7. Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses. 2005 Jan; 21(1):103-9.
    View in: PubMed
    Score: 0,057
  8. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
    View in: PubMed
    Score: 0,030
  9. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host Microbe. 2015 Sep 09; 18(3):354-62.
    View in: PubMed
    Score: 0,030
  10. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses. 2015 Aug; 31(8):776-82.
    View in: PubMed
    Score: 0,029
  11. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol. 2013 Jul; 87(13):7218-33.
    View in: PubMed
    Score: 0,025
  12. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
    View in: PubMed
    Score: 0,022
  13. Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology. 2009 Oct 10; 393(1):56-67.
    View in: PubMed
    Score: 0,020
  14. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72.
    View in: PubMed
    Score: 0,019
  15. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology. 2007 Nov 10; 368(1):172-81.
    View in: PubMed
    Score: 0,017
  16. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007 Feb 01; 44(2):148-53.
    View in: PubMed
    Score: 0,016
  17. A model of directional selection applied to the evolution of drug resistance in HIV-1. Mol Biol Evol. 2007 Apr; 24(4):1025-31.
    View in: PubMed
    Score: 0,016
  18. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006 Dec; 80(23):11776-90.
    View in: PubMed
    Score: 0,016
  19. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol. 2006 May; 80(10):4698-704.
    View in: PubMed
    Score: 0,016
  20. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS. 2006 Mar 21; 20(5):643-51.
    View in: PubMed
    Score: 0,015
  21. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J Virol Methods. 2005 May; 125(2):99-109.
    View in: PubMed
    Score: 0,015
  22. Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res Hum Retroviruses. 2005 Apr; 21(4):285-91.
    View in: PubMed
    Score: 0,014
  23. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses. 2003 Feb; 19(2):133-44.
    View in: PubMed
    Score: 0,012
  24. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol. 2002 Mar; 76(5):2233-44.
    View in: PubMed
    Score: 0,012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.